These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 32966036)

  • 1. Structural Basis for Inhibitor Potency and Selectivity of
    Fienberg S; Eyermann CJ; Arendse LB; Basarab GS; McPhail JA; Burke JE; Chibale K
    ACS Infect Dis; 2020 Nov; 6(11):3048-3063. PubMed ID: 32966036
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of 6'-chloro-N-methyl-5'-(phenylsulfonamido)-[3,3'-bipyridine]-5-carboxamide (CHMFL-PI4K-127) as a novel Plasmodium falciparum PI(4)K inhibitor with potent antimalarial activity against both blood and liver stages of Plasmodium.
    Liang X; Jiang Z; Huang Z; Li F; Chen C; Hu C; Wang W; Hu Z; Liu Q; Wang B; Wang L; Qi Z; Liu J; Jiang L; Liu Q
    Eur J Med Chem; 2020 Feb; 188():112012. PubMed ID: 31911293
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Amidated 3,6-Diphenylated Imidazopyridazines with Potent Antiplasmodium Activity Are Dual Inhibitors of
    Cheuka PM; Centani L; Arendse LB; Fienberg S; Wambua L; Renga SS; Dziwornu GA; Kumar M; Lawrence N; Taylor D; Wittlin S; Coertzen D; Reader J; van der Watt M; Birkholtz LM; Chibale K
    ACS Infect Dis; 2021 Jan; 7(1):34-46. PubMed ID: 33319990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 2,8-Disubstituted-1,5-naphthyridines as Dual Inhibitors of
    Dziwornu GA; Seanego D; Fienberg S; Clements M; Ferreira J; Sypu VS; Samanta S; Bhana AD; Korkor CM; Garnie LF; Teixeira N; Wicht KJ; Taylor D; Olckers R; Njoroge M; Gibhard L; Salomane N; Wittlin S; Mahato R; Chakraborty A; Sevilleno N; Coyle R; Lee MCS; Godoy LC; Pasaje CF; Niles JC; Reader J; van der Watt M; Birkholtz LM; Bolscher JM; de Bruijni MHC; Coulson LB; Basarab GS; Ghorpade SR; Chibale K
    J Med Chem; 2024 Jul; 67(13):11401-11420. PubMed ID: 38918002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heterologous Expression, Purification, and Functional Analysis of the
    Sternberg AR; Roepe PD
    Biochemistry; 2020 Jul; 59(27):2494-2506. PubMed ID: 32543181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fragment-based virtual screening discovers potential new Plasmodium PI4KIIIβ ligands.
    Ibezim A; Madukaife MS; Osigwe SC; Engel N; Karuppasamy R; Ntie-Kang F
    BMC Chem; 2022 Mar; 16(1):19. PubMed ID: 35331319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel Plasmodium falciparum PI4KB inhibitors as potential anti-malarial drugs: Homology modeling, molecular docking and molecular dynamics simulations.
    Ibrahim MAA; Abdelrahman AHM; Hassan AMA
    Comput Biol Chem; 2019 Jun; 80():79-89. PubMed ID: 30928871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification, Characterization, and Optimization of 2,8-Disubstituted-1,5-naphthyridines as Novel Plasmodium falciparum Phosphatidylinositol-4-kinase Inhibitors with in Vivo Efficacy in a Humanized Mouse Model of Malaria.
    Kandepedu N; Gonzàlez Cabrera D; Eedubilli S; Taylor D; Brunschwig C; Gibhard L; Njoroge M; Lawrence N; Paquet T; Eyermann CJ; Spangenberg T; Basarab GS; Street LJ; Chibale K
    J Med Chem; 2018 Jul; 61(13):5692-5703. PubMed ID: 29889526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 5-(3-(methylsulfonyl)phenyl)-3-(4-(methylsulfonyl)phenyl)-3H-imidazo[4,5-b]pyridine as novel orally bioavailable and metabolically stable antimalarial compound for further exploration.
    Kundu M; Dutta A; Roy KK; Mal SK; Karmakar S; Mandal A; Mondal SK; Kumar S; Saha S; Pradhan S; Sarkar R; Chakrabarti M; Malik PK; Banerjee M
    Chem Biol Drug Des; 2023 Mar; 101(3):690-695. PubMed ID: 36322010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3D QSAR, pharmacophore and molecular docking studies of known inhibitors and designing of novel inhibitors for M18 aspartyl aminopeptidase of Plasmodium falciparum.
    Kumari M; Chandra S; Tiwari N; Subbarao N
    BMC Struct Biol; 2016 Aug; 16():12. PubMed ID: 27534744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics of the Plasmodium falciparum PK5 ATP-binding site: implications for the design of novel antimalarial agents.
    Keenan SM; Welsh WJ
    J Mol Graph Model; 2004 Jan; 22(3):241-7. PubMed ID: 14629982
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective activity of biflavanones from Garcinia kola against Plasmodium infection.
    Konziase B
    J Ethnopharmacol; 2015 Aug; 172():214-8. PubMed ID: 26129936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In silico identification of promiscuous scaffolds as potential inhibitors of 1-deoxy-d-xylulose 5-phosphate reductoisomerase for treatment of Falciparum malaria.
    Wadood A; Ghufran M; Hassan SF; Khan H; Azam SS; Rashid U
    Pharm Biol; 2017 Dec; 55(1):19-32. PubMed ID: 27650666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI4-kinase and PfCDPK7 signaling regulate phospholipid biosynthesis in Plasmodium falciparum.
    Maurya R; Tripathi A; Kumar M; Antil N; Yamaryo-Botté Y; Kumar P; Bansal P; Doerig C; Botté CY; Prasad TSK; Sharma P
    EMBO Rep; 2022 Feb; 23(2):e54022. PubMed ID: 34866326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibitors of Plasmodium falciparum glycogen synthase-3 (PfGSK-3): New antimalarial agents?
    Masch A; Kunick C
    Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1644-9. PubMed ID: 25861860
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First homology model of Plasmodium falciparum glucose-6-phosphate dehydrogenase: Discovery of selective substrate analog-based inhibitors as novel antimalarial agents.
    Alencar N; Sola I; Linares M; Juárez-Jiménez J; Pont C; Viayna A; Vílchez D; Sampedro C; Abad P; Pérez-Benavente S; Lameira J; Bautista JM; Muñoz-Torrero D; Luque FJ
    Eur J Med Chem; 2018 Feb; 146():108-122. PubMed ID: 29407943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the structural requirements in multiple chemical scaffolds for the selective inhibition of Plasmodium falciparum calcium-dependent protein kinase-1 (PfCDPK-1) by 3D-pharmacophore modelling, and docking studies.
    Aher RB; Roy K
    SAR QSAR Environ Res; 2017 May; 28(5):390-414. PubMed ID: 28562086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anticancer human mTOR inhibitor sapanisertib potently inhibits multiple
    Arendse LB; Murithi JM; Qahash T; Pasaje CFA; Godoy LC; Dey S; Gibhard L; Ghidelli-Disse S; Drewes G; Bantscheff M; Lafuente-Monasterio MJ; Fienberg S; Wambua L; Gachuhi S; Coertzen D; van der Watt M; Reader J; Aswat AS; Erlank E; Venter N; Mittal N; Luth MR; Ottilie S; Winzeler EA; Koekemoer LL; Birkholtz LM; Niles JC; Llinás M; Fidock DA; Chibale K
    Sci Transl Med; 2022 Oct; 14(667):eabo7219. PubMed ID: 36260689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational and experimental elucidation of Plasmodium falciparum phosphoethanolamine methyltransferase inhibitors: Pivotal drug target.
    Singh J; Vijay S; Mansuri R; Rawal R; Kadian K; Sahoo GC; Kumar M; Sharma A
    PLoS One; 2019; 14(8):e0221032. PubMed ID: 31437171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK-ing New Malaria Chemotherapy.
    Hassett MR; Roepe PD
    Trends Parasitol; 2018 Nov; 34(11):925-927. PubMed ID: 29934102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.